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ABSTRACT 
Ten brands of blister-packed paracetamol tablet and twenty brands of paracetamol syrup marketed in Nigeria were evaluated 
for their microbial quality. While no microbial contaminant was isolated from all blistered-packed paracetamol tablets, ten of 
syrups were contaminated with organisms such as Escherichia coli, Klebsiellas spp, Pseudomonas aeruginosa and Staphylococcus 
aureus at 14.3, 21.4, 21.4 and 42.9% occurrence respectively. Penicillium spp was isolated from two brands. Antibiotic 
susceptibility profile revealed all bacterial isolates to be multidrug resistant with Escherichia coli resistant to all antibiotics 
tested, while Staphylococcus aureus isolates were sensitive to Oxacillin, Cefuroxime and vancomycin. Pseudomonas aeruginosa 
isolates were sensitive to ofloxacin and gentamycin while Klebsiella isolates were sensitive to ofloxacin and nitrofurantoin. The 
study concluded that compliance with the provisions of good manufacturing practice as well as good quality control play role in 
determining the microbial bioburden of pharmaceutical products while isolation of multi-drug resistant organisms calls for 
establishment and adherence to antibiotics use policy in Nigeria. 
Key Words: Blister-pack, multidrug resistance, good manufacturing practice, quality control, bioburden. 
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Résumé:  
Dix marques de comprimé de paracétamol boursouflée-emballés et vingt marques de sirop de paracétamol commercialisés au 
Nigeria étaient évaluées pour leurs qualités microbienne. Bien qu'aucun contaminant microbien était isolé à partir de tous les 
comprimés de paracétamol boursouflée-emballés, dix de sirops étaient contaminés par des organismes tels que : Escherichiacoli, 
Klebsiellaspp, Pseudomonasaeruginosaet de Staphylococcusaureusà14,3, 21,4, 21,4et42,9% respectivementen 
l’occurrence.Penicilliumsppétait isoléà partir de deuxmarques. Profilde sensibilité antibiotiquea révélé 
qu’Escherichiacoliestrésistantes àtouslesantibiotiques examinés, tandis quelesisolâtesde Staphylococcusaureusétaient sensibles 
àl'oxacilline, céfuroximeet la vancomycine. Les IsolâtesdePseudomonasaeruginosaétaientsensiblesà l'ofloxacineetlagentamicinependant 
que les isolâtesdeKlebsiellaétaientsensiblesà l'ofloxacinela nitrofurantoïne. Alors, on peut concluque la 
conformitéauxdispositionsdebonnes pratiques de fabricationvis-à-vis le contrôlede bonne qualité prends part dansla détermination 
de lacharge-biologie microbiennedesproduits pharmaceutiques pendant que isolement des organismes résistants aux nombreux 
médicaments demandentpour l'établissementet l'adhésionau politique d’utilisation des antibiotiquesau Nigeria. 




Pharmaceutical preparations can be classified into 
sterile and non-sterile products. While sterile 
products are expected to be absolutely free of all 
microbes, non-sterile products are not to be free of all 
forms of microbes although there are limits as to the 
permissible levels of these contaminants in such 
pharmaceutical products(1). 
Microorganisms possess diverse metabolic activities 
and are likely to present a variety of hazards (for 
examples, infections, toxicity, degradation of 
formulations) both to the user and to the stability of 
the products, if allowed to persist. Limits have 
therefore been set for the presence of microorganisms 
in medicines by commissions as European 
Pharmacopoeia commission, which vary depending 
on the product and its intended use. However, 
microbial contamination over and above these 
pharmacopoeia levels is a global problem which is 
still being reported in distributed medicines 
worldwide (2). The most commonly reported 
microbial hazards found in liquid medicines as 
syrups are pseudomonads and their related Gram-
negative rods, with spores (bacterial and fungal) 
predominating in dry tablets, capsules and cosmetic 
powders. Occurrence of true pathogens as Salmonella  
spp in syrups has been reported (3, 4).   
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The risk (likelihood of harm actually occurring) 
associated with delivery of contaminated products is 
less clearly determined. It will depend upon the type 
of microorganisms present, the infective dose 
(dependent on the ability of the formulation to 
encourage microbial survival and level of 
preservative protection built with it), the route of 
administration of the product and the host’s 
resistance to infection (including the immune status 
or the degree of tissue damage at the site of 
application).   
The presence of the species as Escherichia spp, 
Klebsiella spp, Pseudomonas spp, Proteus spp, 
Enterococcus spp, Micrococcus spp, Salmonella spp, 
Staphylococcal spp, Bacillus spp, Aerobacter spp, 
Aspergillus spp as well as Penicillium spp in syrups, 
capsules and tablets within and outside Nigeria has 
been reported (3, 5-11).  
The nature of the ingredients, the quality of the 
vehicle and the care and attitude of personnel 
involved in their handling will determine the 
incidence of microflora in non-sterile products (12). 
However, since raw materials, manufacturing 
environment, packaging materials and personnel 
have been implicated as potential sources of 
contaminants in pharmaceutical products, it implies 
that pharmaceutical preparations can be 
contaminated at the point of production and 
packaging by the manufacturer or use by the 
consumers. 
This study aimed at comparing the microbial quality 
of some blister-packed paracetamol tablets to that of 
paracetamol syrups marketed in Nigeria as well as 
identifying the source(s) of such contaminants and 
the potential health hazard implication of such 
contaminants on the populace.  
MATERIALS AND METHODS 
Media                                                                                       
Nutrient broth, nutrient agar, MacConkey agar, 
Mannitol salt agar, Cetrimide agar, Mueller-Hinton 
agar, Salmonella-Shigella agar,  Saboraud Dextrose 
agar; all ATER products from Topley House 52, Wash 
Lane, Bury, Lanchashire BL96AS, UK. 
Preparation of tablet dispersion: 
Two tablets of each brand of blister-packed 
paracetamol were aseptically removed directly into 
10mL sterile normal saline and dispersed. Tablet 
dispersions were mixed in a vortex mixer for 5 
minutes to dislodge possible microbial cells. The solid 
particles settled down and the supernatants were 
used. 
Determination of microbiological quality of tablets: 
One milliliter aliquot of each brand’s dispersion was 
seeded in nutrient agar, poured and allowed to set in 
plates (in duplicates). The procedure was repeated 
using MacConkey agar medium, Mannitol salt agar 
medium, cetrimide agar medium, Salmonella-Shigella 
agar and Saboraud Dextrose agar medium. The 
Saboraud Dextrose agar plates were incubated at 25 
oC for 72-96 hours while the other agar plates were 
incubated at 37 oC for 48 hours before they were 
observed for growth. 
Determination of microbiological quality of syrups: 
1 in 10, 1 in 100 and 1 in 1000 dilutions of each 
paracetamol syrup in sterile peptone water was made 
and 0.1mL of each dilution was seeded in nutrient 
agar medium, MacConkey agar medium, Mannitol 
salt agar, Cetrimide agar medium, 
Salmonella/Shigella agar medium as well as 
Saboraud Dextrose agar medium contained in sterile 
Petri dishes (in duplicates). All the plates were 
incubated at 37oC for 24-48 hours except the Saboraud 
Dextrose agar plates that were incubated at 25oC for 
72-96 hours before they were observed for growth. 
Bacterial isolates from the plates that showed growth 
were subjected to standard microbiologic 
identification tests based on colony morphology, and 
conventional biochemical tests to confirm their 
identity and/or purity.  
Antibiotic susceptibility profiling: 
Susceptibility of the Gram-negative and Gram-
positive isolates to eight and three antimicrobial 
agents respectively was tested by the disc diffusion 
technique according to the guidelines by the Clinical 
and Laboratory Standards Institute (13). The Gram-
negative antibiotic disc contained augmentin (30 µg); 
ofloxacin (5 µg); gentamycin (10 µg); nalidixic acid (30 
µg); nitrofurantoin (200 µg); cotrimoxazole (25 µg); 
amoxycillin (25 µg) and tetracycline (25 µg) while the 
Gram-positive antibiotic single disc comprised of  
oxacillin (1µg); cefuroxime (30µg); and vancomycin 
(30 µg). 
Four or five colonies of each test organism taken from 
a nutrient agar culture plate was inoculated into 10 
mL of sterile distilled water using a sterile loop. The 
suspension was thoroughly mixed with a spin mixer. 
The resulting suspension was adjusted to a turbidity 
of 0.5 McFarland standard. This was then applied to 
the surface of oven-dried Mueller Hinton agar and 
spread evenly with a sterile swab stick. The 
inoculated plates were incubated at 37oC for 20 
minutes for acclimatization and growth of the 
inocula. Antibiotic discs (Abtek, Liverpool, UK) were 
then lightly but firmly pressed onto the surface of the 
plates using a pair of sterile forceps. The plates were 
then refrigerated at 4oC for thirty minutes to ensure 
adequate diffusion of antibiotics. E. coli ATCC 25922 
was used as control strain. All plates were incubated 
at 37oC for 18 hours. The diameters of inhibition 
zones were measured in millimetres and interpreted 
according to CLSI manual. 
153 
 
RESULTS                                                                                     
Of the ten selected brands of blister-packed 
paracetamol tablet used for the study, only one was 
imported from India while the remaining nine were 
manufactured in Nigeria. All the brands used have 
their identities revealed by indicating the date of 
manufacture, expiry date, NAFDAC number as well 
as the address of the manufacturer as shown in Table 
1. 
The container disclosures of all the twenty brands of 
paracetamol syrup, manufactured in Nigeria, used for 
the study are as shown in Table 2.However, of the 
twenty brands of paracetamol syrup used for the 
study, 50% were free of microbial contaminants while 
50% were contaminated with microbial loads ranging 
from 2 x 101 in S13 to 1.05 x 104 cfu/mL in S18 as shown 
in Table 3. 
A total of 14 bacterial isolates comprising of 
Staphylococcus aureus, 42.9%; Klebsiella spp, 21.4%; 
Pseudomonas aeruginosa, 21.4%; and Escherichia coli, 
14.3% as shown in Table 4 were isolated from this 
study. 
Antibiotic susceptibility profiles revealed all Klebsiella 
isolates to be sensitive to ofloxacin, and 
nitrofurantoin, with 2 strains sensitive to gentamycin, 
an aminoglycoside, and 1 strain with intermediate 
sensitivity. They were however resistant to other 
antibiotics tested namely: cotrimoxazole, amoxicillin, 
tetracycline, augmentin and nalidixic acid. All 
Escherichia coli, on the other hand, were resistant to all 
antibiotics tested while one strain of Pseudomonas 
aeruginosa was sensitive to ofloxacin and gentamycin 
while showing intermediate sensitivity to tetracycline. 
One strain was also sensitive to tetracycline with 
intermediate sensitivity to ofloxacin. One other strain 
showed intermediate sensitivity to ofloxacin and 
nitrofurantoin as shown in Table 5 
All Staphylococcus aureus isolated were sensitive to 
oxacillin and cefuroxime, both ß-lactam antibiotics 
with varying sensitivity to vancomycin as shown in 
Table 6 
 
TABLE 1: CONTAINER DISCLOSURE OF EACH BRAND OF BLISTER-PACKED PARACETAMOL TABLET USED FOR THE 
STUDY 
SAMPLE MANUFACTURING DATE EXPIRY DATE NAFDAC NUMBER ADDRESS OF 
MANUFACURER 
T1 + + 04-0633 + 
T2 + + 04-0411 + 
T3 + + 04-1957 + 
T4 + + 04-0101 + 
T5 + + 04-0975 + 
T6 + + 04-1853 + 
T7 + + 04-5762 + 
T8 + + 04-1217 + 
T9 + + 04-1207 + 
















S1 + LO66P + + 
S2 + 452 + + 
S3 + PL7108 + + 
S4 + TPS008 + + 
S5 + 9169 + + 
S6 + L4909 + + 
S7 + P510001 + + 
S8 + 242 + + 
S9 + 08001 + + 
 S10 + 08760507 + + 
S11 + 0254 + + 
 
 
   
S13 + PL 001 + + 
S14 + P05 + + 
S15 + S m 3325 P + + 
S16 + 014251 + + 
S17 + IZ1686 + + 
S18 + 9011 + + 
S19 + PA0405 + + 
S20 + 00111 + + 
TABLE 3: MICROBIAL QUALITY OF EACH PARACETAMOL SYRUP USED FOR STUDY 
 
Paracetamol sample Total viable count 
(cfu/mL 
Organism(s) isolated 
S1 3 x 101 Staphylococcus aureus 
 
S2 2 x 102 Penicillium spp 
 




S5 6.75 x 102 Staphylococcus aureus 
 
S6 Nil  
S7 Nil  
S8 Nil  


























S17 2 x 101 Escherichia coli 
 




S19 1.3 x 102 Escherichia coli 
 
S20 Nil  
 
TABLE 4: PERCENTAGE OCCURRENCE OF ISOLATED BACTERIA IN PARACETAMOL SYRUP SAMPLES 
   
             ISOLATED      
ORGANISM 
  P     PERCENTAGE   PREVALENCE 
Staphylococcus aureus 42.9% 
Klebsiella spp 21.4% 
Pseudomonas aeruginosa 21.4% 
Escherichia coli 14.3% 
 
TABLE 5: ANTIBIOTIC SENSITIVITY PATTERNS OF GRAM-NEGATIVE BACTERIAL ISOLATES OBTAINED FROM 
PARACETAMOL SYRUP SAMPLES 

















S15(a) 0(R) 0 (R) 9 (R) 7 (R) 21 (S) 14 (I) 0 (R) 24 (S) 
S15(b) 0 (R) 6 (R) 20 (S) 0 (R)  13 (I) 0 (R) 0 (R) 0 (R) 
S16(a) 0 (R) 0 (R) 11 (R) 0 (R) 24 (S) 17 (S) 0 (R) 18 (S) 
S16(b) 0 (R) 0 (R) 10 (R) 0 (R) 14 (I) 0 (R) 0 (R) 16 (I) 
S17(c) 0 (R) 13 (R) 0 (R) 0 (R) 11 (R) 0 (R) 0 (R) 9 (R) 
S18(a) 0 (R) 0 (R) 14 (R) 0 (R) 16 (S) 20 (S) 0 (R) 17 (S) 
S18(b) 0 (R) 0 (R) 16 (I) 0 (R) 17 (S) 16 (S) 0 (R) 10 (R) 
S19(c) 0 (R) 0 (R) 0 (R) 0 (R) 12 (R) 0 (R) 0 (R) 10 (R) 




TABLE 6: ANTIBIOTIC SENSITIVITY PATTERNS OF GRAM-POSITIVE BACTERIAL ISOLATES OBTAINED FROM 
PARACETAMOL SYRUP SAMPLES 







S1 13 (S) 25 (S) 15 (I) 
S5 14 S) 24 (S) 15 (I) 
S15 14 (S) 24 (S) 15 (S) 
S16 15(S) 23 (S) 15 (I) 
S18 21 (S) 34 (S) 17 (S) 
  KEY: S – Sensitive; OX = Oxacillin; I – Intermediate; CXM = Cefuroxime; R – Resistant;  VA = Vancomycin 
DISCUSSION 
In the microbiological evaluation of non-sterile 
products, two tests are important namely: the extent 
of contamination test and the nature of the 
contaminant test. These tests are complementary and 
every non sterile product must pass the two tests 
before being released for customer use. While the 
extent of contamination test sets allowable limits for 
microbial contaminants in the product, the nature test 
addresses objectionable pathogenic organisms whose 
presence in the product will render the product 
unsuitable for use irrespective of their number in the 
product.  These two tests were used in this study to 
determine the suitability for use or otherwise of some 
blister-packed paracetamol tablets and paracetamol 
syrups marketed in Nigeria. 
Tablets are compacts drug delivery systems with low 
water content which usually afford them good 
protection against microbial contamination. Spoilage 
and clinical infections resulting from microbial 
contamination of tablets under hot and humid 
conditions of the tropics have been reported (7, 14). 
Tablets also undergo deleterious changes as 
discoloration, weakening of tablets matrixes and 
decreases in the potency of active ingredients when 
improperly stored (15). Potential contamination of 
tablets may arise from heavy microbiological burden 
in raw materials, though this is usually drastically 
reduced by lethal drying stage of wet granulation 
(16). However, the decreasing use of direct 
compression in manufacturing of tablets in 
pharmaceutical industries implies that some 
contaminants may survive up to the compression 
stage. The compression of formulation is known to 
effect some level of microbial destruction but this 
depends on the compression pressure applied, the 
properties of the contaminating organisms, and the 
formulation involved (17, 18). The effects of these 
variables in turn are believed to depend on the 
mechanism of microbial kill which has been proposed 
to include high localized heat shearing forces during 
compression (18, 19). The shear stresses manifested 
during compression depend largely on the principal 
mode of consolidation of the formulation which can 
be by fragmentation of plastic flow, with plastic 
having been shown to be a highly effective 
mechanism for microbial kill even at low compression 
pressures (17, 20). Binding agents employed in 
formulations are known to undergo a high degree of 
plastic deformation during compression and are 
forced into their inter-particulate spaces where they 
increase the area of contact between the particles and 
form strong solid bounds. All these factors played 
role in the result obtained for tablets used for this 
study as none of the tablets used for the study was 
contaminated by any form of microbial contaminant. 
Syrups, on the other hand, usually consist of active 
ingredient, sugar, vehicle and/or preservative. 
The ability of the bacteria isolated in this study to 
survive in syrup can be attributed to water activity of 
those brands of paracetamol syrup studied. 
 Reduced water activity will greatly assist in the 
prevention of microbial proliferation in 
pharmaceutical products. Because the water activity 
requirements for different Gram-reactive bacteria, 
bacterial spores, yeast and moulds have been 
described (12), the appropriate microbial limit testing 
program for products of differing water activities can 
be established. For instance, Gram-negative bacteria 
such as Pseudomonas aeruginosa, Escherichia coli, and 
Salmonella species will not proliferate or survive in 
products with water activities below 0.91 while 
Gram-positive bacteria like Staphylococcus aureus will 
not proliferate below 0.86, and Aspergillus niger will 
not proliferate below 0.77. Furthermore, most 
osmophilic yeast and xerophilic fungi will not 
proliferate below 0.60 (21). 
Suffice it to say that the water activity of the product 
is a function of the organism to be excluded from the 
product. In this study in particular, it can be said that 
the water activity of all the paracetamol tablets and 
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some brands of paracetamol syrup, where neither 
bacteria nor fungi were isolated, was below 0.60. 
Of the 50% contaminated paracetamol syrup samples 
used, S15, S16 and S18 were heavily contaminated with 
3 strains of bacteria namely: Klebsiella spp, 
Pseudomonas aeruginosa and Staphylococcus aureus 
while S19 was contaminated with only Escherichia coli 
and other samples with Staphylococcus aureus with the 
exception of S2 and S13 that were contaminated with 
Penicillium spp. 
Klebsiella spp are found in the respiratory, intestinal, 
and urinogenital tracts of animals and humans. 
However, when Klebsiella moves outside the gut, it 
can cause a serious infection. Thus, its presence in the 
assayed samples is also an indication of unhygienic 
conditions, and may have originated from 
pharmaceutical personnel. The presence of 
Staphylococcus aureus does not always mean that the 
consumption of medicines are potentially being 
hazardous to users as not all the strain of 
Staphylococcus sp. can necessarily produce enterotoxin 
where higher infectious dose (105-106CFU/mL) is 
required (6). Staphylococcus aureus may however cause 
a significant deterioration in the health status of 
patients, particularly those who are immunologically 
compromised and of infants with an immature 
immune system (22). Staphylococcus sp. might 
transmit from hands of handler during the 
preparation of drugs. 
The presence of Escherichia coli is a good indicator of 
fecal contamination resulting from water supply. 
Incidence of infantile diarrhoea associated with E. coli 
as a result of poor water supply in Nigeria has been 
reported (23). However, the presence of all the 
isolated organisms in this study has rendered the 
product from which they were isolated unfit for 
human use, being indicator organisms according to 
the United States Pharmacopoeia (USP). Organisms as 
Salmonella sp., Pseudomonas aeruginosa, Escherichia coli, 
Staphylococcus aureus, and Candida albicans have been 
recommended as indicators of pathogenic 
microorganism contaminants of syrups (24).   
Antibiotic sensitivity profiles revealed all isolates to 
be multidrug resistant as they were resistant to two or 
more antibiotics used for the study. Ofloxacin and 
Nitrofurantoin are the drugs of choice as far as this 
study is concerned as majority of the isolates 
displayed highest degree of susceptibility to them. 
However, all the Gram-positive isolates were 
sensitive to all the antibiotics against which they were 
tested in this study.  
Quality control, as part of quality assurance, involves 
the sampling and testing of starting materials, 
intermediate, bulk and finished products and 
packaging materials to ensure compliance with 
appropriate standards and specifications. Quality 
Assurance is the totality of the process undertaken to 
ensure absolute quality of a product. Quality 
Assurance is Quality Control plus Good 
Manufacturing Practices (GMP), i.e. the product is 
manufactured through laid down procedures, contain 
necessary ingredients in correct proportions and of 
right purity, packed in proper containers and with 
proper labels. The pharmaceutical industries have an 
obligation to design, test and produce dosage forms 
that provide the consumer with products having the 
attributes of quality, purity, uniformity of content, 
stability, safety and physiological availability. These 
requirements necessitate the total involvement of 
corporate personnel with formal system of checks and 
balances. It is only through well organized, 
adequately staffed and accurately performed process 
and dosage form control before, during and after 
production that adequate quality assurance of the 
product can be achieved (25). 
The presence of antibiotic-resistant organisms in 
paracetamol syrup as shown in this study is of 
concern as they pose danger to children especially the 
immunocompromised ones in whom they can 




It can be concluded that since no organism was 
isolated from all paracetamol tablets studied while 
organisms were isolated from some paracetamol 
syrup samples studied, it follows that manufacturing 
processes to which both the drug substance and the 
excipients were subjected have effect on the microbial 
quality of the final dosage form. While none of the 
blistered-packed paracetamol tablets studied pose 
threat health-wise to the consumers, isolation of 
antibiotic-resistant contaminants from some samples 
of paracetamol syrup studied emphasize a need for 
rational use of antibiotics in the country. 
Moreover, product of good microbial quality can be 
guaranteed through quality control and adherence to 
the provisions of good manufacturing practices. Also, 
low water activity can aid reduction in vulnerability 
of formulations to microbial contamination provided 
the pharmaceutical products are made from 
ingredients of good microbial quality, when 
manufacturing environments do not foster microbial 
contamination, when there are processes that 
inherently reduce the microbial content, to mention 
but a few. 
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